NCT01855269

Brief Summary

The aim was to test the hypothesis that oral administration of Lactobacillus reuteri in a prospective randomized controlled study would improve symptoms of infantile colic.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
74

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2013

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2013

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 13, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 16, 2013

Completed
Last Updated

May 16, 2013

Status Verified

May 1, 2013

Enrollment Period

10 months

First QC Date

May 13, 2013

Last Update Submit

May 15, 2013

Conditions

Keywords

probioticinfantile colic

Outcome Measures

Primary Outcomes (1)

  • Crying time

    Infants crying episodes, feeding and stooling characteristics, growth, weight gain were noted weekly for three weeks

    3 weeks

Secondary Outcomes (1)

  • postpartum depression

    3 weeks

Study Arms (3)

Lactobacillus reuteri

ACTIVE COMPARATOR

Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks

Dietary Supplement: Lactobacillus reuteri

Herbal drop

ACTIVE COMPARATOR

Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks

Dietary Supplement: Herbal drop

Sterile water

PLACEBO COMPARATOR

Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks

Dietary Supplement: placebo sterile water

Interventions

Lactobacillus reuteriDIETARY_SUPPLEMENT

Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks

Also known as: Biogaia
Lactobacillus reuteri
Herbal dropDIETARY_SUPPLEMENT

Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks

Also known as: Babs
Herbal drop
placebo sterile waterDIETARY_SUPPLEMENT
Sterile water

Eligibility Criteria

Age3 Weeks - 3 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • infants three weeks to three months
  • infants with colic three hours of crying on three days in the week
  • infants feeding with breast milk
  • infants weighing 2500 to 4000 gram

You may not qualify if:

  • chronic illness
  • gastrointestinal disorders
  • infants received either antibiotics or probiotics in the previous week

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sami Ulus CH

Ankara, Turkey, 06120, Turkey (Türkiye)

Location

Related Publications (1)

  • Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007 Jan;119(1):e124-30. doi: 10.1542/peds.2006-1222.

MeSH Terms

Conditions

CryingColic

Condition Hierarchy (Ancestors)

Nonverbal CommunicationCommunicationBehaviorInfant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Nilgün Karadağ, MD

    MD, Sami Ulus CH

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc Prof

Study Record Dates

First Submitted

May 13, 2013

First Posted

May 16, 2013

Study Start

April 1, 2012

Primary Completion

February 1, 2013

Study Completion

April 1, 2013

Last Updated

May 16, 2013

Record last verified: 2013-05

Locations